Bio-Rad Laboratories, Inc. BIO
381.57 USD +12.57 (+3.41%)
At closeNov 6, 2026, 5:05 PM EST
381.57 0.00 0.00%
After hours · Nov 6, 5:05 PM ET
365.16 Day range 384.62
241.71 52-week range 390.34
- YTD
- +25.93%
- 1 year
- +24.47%
News
benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $390 to $440.
globenewswire.com Medicus Pharma to Present at BIO-Europe 2026 Medicus Chief Medical Officer will Highlight Company's Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs Medicus Chief Medical Officer will Highlight…
marketbeat.com What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings Call Bio-Rad Laboratories NYSE: BIO reported modest third-quarter revenue growth, its first currency-neutral increase of 2026, as gains in clinical diagnostics and digital PCR instruments helped offset…
seekingalpha.com Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript
zacks.com Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.61 per share. This compares to earnings of $2.26 per share a year ago.
benzinga.com Bio-Rad Laboratories Q3 2026 Earnings Call Transcript Bio-Rad Laboratories (NYSE:BIO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Bio-Rad Laboratories Affirms FY2026 Sales Guidance of $2.506B-$2.596B vs $2.588B Est Bio-Rad Laboratories (NYSE:BIO) affirms FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.588 billion estimate.
benzinga.com Bio-Rad Laboratories Q3 Adj. EPS $2.65 Beats $2.23 Estimate, Sales $656.400M Beat $649.950M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.65 per share which beat the analyst consensus estimate of $2.23 by 18.83 percent. This is a 17.26 percent increase over earnings of…
businesswire.com Bio-Rad Reports Third-Quarter 2026 Financial Results HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for…
prnewswire.com BIO-TECHNE DECLARES DIVIDEND MINNEAPOLIS, Nov. 3, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September…
globenewswire.com Cipher, a Prosegur Company, and BIO-key Announce Technology Integration to Expand Identity Security Offering, Starting in Portugal Cipher, a Prosegur Company, and BIO-key (BKYI) Announce Technology Integration to Expand Identity Security Offering Internationally, Starting in Portugal.
benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $370 to $390.
benzinga.com Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330 Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from $300 to $330.- benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $320 to $370.
- benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330 Wells Fargo analyst Evan Stampler maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $310 to $330.
- benzinga.com Bio-Rad Laboratories Lowers FY2026 Sales Guidance of $2.506B-$2.596B vs $2.567B Est Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.567 billion estimate.
benzinga.com Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.62 per share which beat the analyst consensus estimate of $1.75 by 49.71 percent. This is a 0.38 percent increase over earnings of…
benzinga.com Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle.
benzinga.com Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today Nasdaq sinks 1.1% as AMAT, MU, ORCL and Vertiv crater on AI capex jitters, while WTI tops $106 and the 10-year yield hovers near 4.6% on stalled US-Iran talks.
benzinga.com Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HIVE, TE, AUTL, GENI, BRC, BIO, BL, RBLX, ZETA, and D.- benzinga.com 'Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad' - WSJ https://www.wsj.com/business/deals/activist-elliott-builds-big-stake-in-life-science-tools-supplier-bio-rad-c99b23fa
benzinga.com RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and announces $320 price target.
benzinga.com Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on Hormuz news and Trump set 25% EU auto tariffs.- benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290 Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.
- benzinga.com Bio-Rad Laboratories Lowers FY2026 Sales Guidance from $2.596B-$2.622B to $2.506B-$2.596B vs $2.630B Est Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2.506 billion-$2.596 billion vs $2.630 billion estimate.
benzinga.com Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call - benzinga.com Bio-Rad Laboratories Q1 Adj. EPS $1.89 Misses $1.98 Estimate, Sales $592.100M Beat $588.875M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $1.89 per share which missed the analyst consensus estimate of $1.98 by 4.55 percent. This is a 25.59 percent decrease over earnings of…
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $300 Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price target from $375 to $300.
benzinga.com Pinterest Posts Downbeat Results, Joins DraftKings, Toast, Expedia And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Bio-Rad Laboratories Sees FY2026 Sales $2.596B-$2.622B vs $2.630B Est Full-Year 2026 Financial OutlookBio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5…
benzinga.com Earnings Summary: Bio-Rad Laboratories Q4 
benzinga.com Bio-Rad Laboratories Q4 Adj. EPS $2.51 Misses $2.70 Estimate, Sales $693.200M Beat $688.758M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.51 per share which missed the analyst consensus estimate of $2.70 by 7.04 percent. This is a 13.45 percent decrease over earnings of…- benzinga.com Earnings Scheduled For February 12, 2026
benzinga.com Qiagen Explores Possible Sale After New Buyer Talks: Report Qiagen is reviewing strategic options, including a potential sale, after renewed takeover interest from several buyers.- benzinga.com Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375 Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and raises the price target from $350 to $375.
- benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340 Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $265 to $340.
benzinga.com CORRECTION: Bio-Rad Laboratories Q3 Adj. EPS $2.26 Beats $1.93 Estimate, Sales $653.000M Beat $651.301M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.26 per share which beat the analyst consensus estimate of $1.93 by 16.92 percent. This is a 11.88 percent increase over earnings of…- benzinga.com Bio-Rad Laboratories Affirms FY2025 Sales Guidance of $2.567B-$2.593B vs $2.593B Est Full-Year 2025 Financial OutlookBio-Rad is maintaining its financial outlook for the full year 2025. The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 0 to…
benzinga.com Earnings Scheduled For October 29, 2025 
benzinga.com Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday - benzinga.com Earnings Scheduled For July 31, 2025
- benzinga.com Earnings Scheduled For May 1, 2025
- benzinga.com Earnings Scheduled For February 13, 2025
- benzinga.com Earnings Scheduled For February 15, 2024 Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
- benzinga.com Earnings Scheduled For October 26, 2023 Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.
- benzinga.com Earnings Scheduled For August 3, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
- benzinga.com Earnings Scheduled For May 4, 2023 Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
- benzinga.com Earnings Scheduled For February 16, 2023 Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal…